Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184604 | 1.00 | TDP1 (0.45) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL18311461 | 0.86 | TDP1 (0.56) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL27557557 | 0.85 | ALDH1A1 (0.56) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL29399544 | 0.83 | TDP1 (0.47) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL22032838 | 0.83 | TDP1 (0.47) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL22983959 | 0.82 | GPR35 (0.50) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL16495121 | 0.82 | ALDH1A1 (0.41) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL29399645 | 0.82 | ALDH1A1 (0.47) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL25238980 | 0.82 | GPR35 (0.45) | TDP1ATMALDH1A1MAPTBCHE | |
| SCHEMBL15404891 | 0.82 | ALDH1A1 (0.41) | TDP1ATMALDH1A1MAPTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4658646-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-105814048-B | Fused tricyclic benzimidizole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| CN-105814048-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015086525-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | TDP1 3606/4885ATM 2247/4885ALDH1A1 2072/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | TDP1 1302/4885ATM 1813/4885ALDH1A1 3930/4885 |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TDP1 284/4885ATM 2581/4885ALDH1A1 205/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | TDP1 382/4885ATM 335/4885ALDH1A1 3885/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | TDP1 2372/4885ATM 3544/4885ALDH1A1 336/4885 |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | TDP1 73/4885ATM 364/4885ALDH1A1 693/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | TDP1 4430/4885ATM 2365/4885ALDH1A1 743/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | TDP1 3540/4885ATM 3158/4885ALDH1A1 3268/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | TDP1 1516/4885ATM 713/4885ALDH1A1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.